Quanterix Corporation (QTRX)
| Market Cap | 141.41M -38.0% |
| Revenue (ttm) | 153.41M +22.0% |
| Net Income | -123.11M |
| EPS | -2.63 |
| Shares Out | 47.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 323,255 |
| Open | 3.110 |
| Previous Close | 3.120 |
| Day's Range | 2.990 - 3.110 |
| 52-Week Range | 2.150 - 8.770 |
| Beta | 1.07 |
| Analysts | Hold |
| Price Target | 3.00 (+0.33%) |
| Earnings Date | Aug 10, 2026 |
About QTRX
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include assays include all components required to run enzyme-based immunoassay, s... [Read more]
Financial Performance
In 2025, Quanterix's revenue was $138.90 million, an increase of 1.07% compared to the previous year's $137.42 million. Losses were -$107.15 million, 178.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for QTRX stock is "Hold." The 12-month stock price target is $3.0, which is an increase of 0.33% from the latest price.
News
Quanterix price target lowered to $3 from $4 at Canaccord
Canaccord lowered the firm’s price target on Quanterix (QTRX) to $3 from $4 and keeps a Hold rating on the shares. The firm updated its model following Q2 results said…
Quanterix Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company completed its Akoya integration, achieved $85 million in synergies, and restructured its commercial organization for deeper market focus. Diagnostics growth is driven by LucentAD Complete, with FDA approval and payer coverage progressing. Revenue is expected to improve in Q4, and cash flow breakeven is targeted for next year.
Quanterix price target lowered to $3 from $4 at TD Cowen
TD Cowen lowered the firm’s price target on Quanterix (QTRX) to $3 from $4 and keeps a Hold rating on the shares. The firm said they posted a weak Q2…
Quanterix Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 34% as reported but fell 23% pro forma, prompting a guidance cut to $142–$148 million for the year. Leadership changes and commercial reorganization aim to address execution issues, while diagnostics, especially Alzheimer's testing, is a key growth focus with new insurance coverage and product launches.
Quanterix Earnings release: Q2 2026
Quanterix released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Quanterix Slides: Q2 2026
Quanterix has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Quanterix Quarterly report: Q2 2026
Quanterix has published its Q2 2026 quarterly earnings report on August 10, 2026.
Quanterix appoints Gute as Chief Commercial Officer
Quanterix (QTRX) announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the…
Quanterix reports Q2 EPS ($1.04), consensus (41c)
Reports Q2 revenue $32.9M, consensus $37.46M. “We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue ...
Quanterix sees FY26 revenue $142M-$148M, consensus $169.86M
Quanterix (QTRX) currently expects revenues of $142M-148M, which assumes no underlying improvement in the academic or pharmaceutical end markets, compared to its earlier expectation for annual revenue...
Quanterix Names Jim Gute Chief Commercial Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed ...
Quanterix Releases Financial Results for the Second Quarter of 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026. “...
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuit...
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026,...
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Anthem Blue Cross, Blue Shield establish commercial coverage for LucentAD
The company “announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD(R) ...
Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical ...
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diag...
Quanterix Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing its diagnostics strategy with a five-marker Alzheimer's test, aiming for FDA approval and strong payer support in the second half. Investments in commercial capabilities, innovation, and leadership are expected to drive growth and margin expansion, with cash flow breakeven targeted by year-end.
Quanterix appoints Faessler as Chief Financial Officer
Quanterix (QTRX) announced the appointment of Jason Faessler as the Company’s new Chief Financial Officer, effective June 22. Faessler joins Quanterix from Bruker Corporation (BRKR), where he served a...
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the ap...
Quanterix appoints Geoff Albrecht as general manager, Diagnostics
Quanterix Corporation (QTRX) announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. Starting with Alzheimer’s Disease Diagnostics, Albrecht will lead ...
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the ap...
Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that s...
Quanterix announces CFO transition
Quanterix (QTRX) “announced that Vandana Sriram, its CFO will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026,…